Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/2 Clinical Trial of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma Patients

NCT04614909 is registered in ClinicalTrials.gov with Nader Sanai as lead sponsor.

NCT NCT04614909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/2 Clinical Trial of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma Patients
Lead sponsor
Nader Sanai
Phase
Phase 1
Overall status
Completed
Start date
January 11, 2021
Completion date
May 28, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme, glioblastoma multiforme, adult